Last reviewed · How we verify

NCT05894642

Characterization of Long Covid Pain in Primary Care

Status unknown Last updated 8 June 2023
What this trial tests

trial testing 0 in Long COVID in 300 participants. Status unknown.

Timeline
15 May 2022
Primary endpoint
1 December 2023
1 February 2024

Quick facts

Lead sponsorUniversity of Valladolid
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment300
Start date15 May 2022
Primary completion1 December 2023
Estimated completion1 February 2024
Sites1 location across Spain

Drugs / interventions tested

Conditions studied

Sponsor

University of Valladolid

Who can join

Adults 18 to 70, any sex, with Long COVID or Chronic Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Justification: among the sequelae of Covid-19 in clinical practice we frequently find persistent neuromusculoskeletal pain. Prevalence data and the underlying mechanisms of such pain are very limited in the scientific literature. Therefore, with this research we will try to answer these questions. Main objective: to determine and characterize persistent musculoskeletal pain in Covid-19 patients. Method: two phases. First, a descriptive cross-sectional study will be carried out to estimate the prevalence of Long Covid Pain (LCP). Second phase, a case-control study will be carried out using the sample obtained in the first phase as the population. The sample will be divided into two groups: post-Covid-19 patients with LCP and post-Covid-19 patients without persistent pain (control group). The two groups will be matched according to sex, age and level of severity of the pathology. An assessment and comparison between groups will be made of the following variables: central sensitization, healthy physical condition and blood test values, which will be evaluated by means of physical examination, questionnaires and laboratory tests. Applicability of the results: this is a pioneering project at the national level, which would determine more reliably the prevalence of LCP in postcovid and could be a first step in the search for the best therapeutic strategies for these patients. This would help to improve the quality of life of these patients and to better manage the social and healthcare resources used in their treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of 0

Trials testing the same drug.

Other recruiting trials for Long COVID

Currently open trials in the same condition.

Other University of Valladolid trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05894642.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing